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Monocyte chemoattractant protein-1 (MCP-1)/CCL2 plays an important role in the 
initiation and progression of cancer. We previously reported that in 4T1 murine breast 
cancer, non-tumor stromal cells, including macrophages, were the major source of 
MCP-1. In the present study, we analyzed the potential mechanisms by which MCP-1 
is upregulated in macrophages infiltrating 4T1 tumors. We found that cell-free culture 
supernatants of 4T1 cells (4T1-sup) markedly upregulated MCP-1 production by peri-
toneal inflammatory macrophages. 4T1-sup also upregulated other MCPs, such as 
MCP-3/CCL7 and MCP-5/CCL12, but modestly upregulated neutrophil chemotactic 
chemokines, such as KC/CXCL1 or MIP-2/CXCL2. Physicochemical analysis indicated 
that an approximately 2–3  kDa 4T1 cell product was responsible for the capacity of 
4T1-sup to upregulate MCP-1 expression by macrophages. A neutralizing antibody 
against granulocyte/macrophage colony-stimulating factor (GM-CSF), but not mac-
rophage CSF, almost completely abrogated MCP-1-inducing activity of 4T1-sup, and 
recombinant GM-CSF potently upregulated MCP-1 production by macrophages. The 
expression levels of GM-CSF in 4T1 tumors in vivo were higher than other tumors, such 
as Lewis lung carcinoma. Treatment of mice with anti-GM-CSF antibody significantly 
reduced the growth of 4T1 tumors at the injection sites but did not reduce MCP-1 
production or lung metastasis in tumor-bearing mice. These results indicate that 4T1 
cells have the capacity to directly upregulate MCP-1 production by macrophages by 
releasing GM-CSF; however, other mechanisms are also involved in increased MCP-1 
levels in the 4T1 tumor microenvironment.
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inTrODUcTiOn
Infiltration of leukocytes is observed in a number of human 
and mouse cancers (1, 2). Although the composition of tumor-
infiltrating leukocytes and the role they play may vary in each 
tumor, they are generally immunosuppressive and provide a 
microenvironment that favors tumor growth. Thus, identify-
ing the molecular mechanisms by which immunosuppressive 
leukocytes are recruited into tumors is critical and clinically 
important.
Monocyte chemoattractant protein-1 (MCP-1)/CCL2 is 
a chemokine with potent monocyte chemotactic activity. 
It was initially purified from the culture supernatant of a 
human malignant glioma (3) and a monocytic leukemic cell 
line (4), and is identical to the tumor-derived chemotactic 
factor, TDCF (5). Accumulating evidence strongly suggests 
that the production of MCP-1 by tumors is responsible for 
the recruitment of immunosuppressive macrophages that 
promote tumor growth. In a chemically induced skin papil-
loma model, the number of papillomas in MCP-1-deficient 
mice was lower compared to that observed in WT mice (6). 
A vital role of MCP-1 in the initiation and progression of 
colitis-associated colon carcinogenesis was demonstrated by 
using mice deficient in the MCP-1 receptor CCR2 or MCP-1 
blocking agent (7). In addition, neutralization of MCP-1 
resulted in reduced growth and development of prostate 
cancer (8–10), breast cancer (11, 12), and lung cancer (13) in 
mice. Thus, MCP-1 is a candidate molecular target of cancer 
treatment (14).
4T1 breast cancer was a spontaneous mammary tumor 
of a Balb/cC3H mouse. When 4T1 cells are orthotopically 
transplanted into mammary pads of Balb/c mice, they form 
tumors and metastasize to distant organs and tissues, such 
as lung, liver, and bone; thus, providing an excellent model 
to elucidate the mechanisms involved in tumor growth and 
metastasis (15). We previously reported that non-tumor 
stromal cells, but not tumor cells, were the main source of 
MCP-1 in 4T1 tumors, and stromal cell-derived MCP-1 
played a critical role in the spontaneous metastasis of tumor 
cells to the lung (16).
In the present study, we examined the molecular mechanisms by 
which stromal cells, especially infiltrating macrophages, produce 
MCP-1 in 4T1 tumors. We identified granulocyte/macrophage 
colony-stimulating factor (GM-CSF/CSF-2) released by 4T1 
cells as a potent inducer of monocyte chemotactic chemokines, 
including MCP-1, MCP-3, and MCP-5, by inflammatory mouse 
macrophages in  vitro. Inhibition of GM-CSF by a neutralizing 
antibody in vivo significantly reduced tumor size, but not MCP-1 
production or lung metastasis. These results indicate that tumor 
cell-derived GM-CSF promotes tumor progression by tuning 
the tumor-promoting microenvironment by activating tumor-
infiltrating macrophages, but other mechanisms are also involved 
in increased MCP-1 production in the 4T1 tumor microenviron-
ment. Better understanding of the interaction between tumors 
cells and non-tumor cells in tumor stroma may lead to the 
development of novel cancer treatment strategies.
MaTerials anD MeThODs
reagents
RPMI-1640, DMEM, HBSS, and Ultradoma were from Lonza, 
Walkersville, MD, USA. TRIzol reagent was from Invitrogen, 
Grand Island, NY, USA. Fetal bovine serum (FBS) was from 
HyClone, Logan, UT, USA. Recombinant mouse TNFα, M-CSF, 
GM-CSF, normal rat IgG, and neutralizing antibodies against 
mouse TNFα (clone MP6-XT22), mouse M-CSF (clone 131621), 
or mouse GM-CSF (clone MP122E9) were from R&D Systems, 
Minneapolis, MN, USA. Anti-mouse GM-CSF (clone MP122E9, 
LEAF™ purified) was also from BioLegend (San Diego, CA, 
USA). Recombinant human M-CSF and GM-CSF were from 
Peprotech, Rocky Hill, NJ, USA. Thioglycollate (TG) was from 
Difco Laboratories (Detroit, MI, USA). LPS was from Sigma-
Aldrich, St. Louis, MO, USA. [α-32P]dCTP was from Perkin 
Elmer, Cambridge, MA, USA.
Mice
Wild type (WT) C57BL/6 and Balb/c mice were from Charles 
River, Frederick, MD, USA. The generation of Balb/c MCP-
1−/− mice (MMRRC stock No. 037094-UNCC, 29S1(Cg)-
Ccl2tm1.1Tyos/Mmnc) was previously described (16, 17). 
Myeloid cell-specific MCP-1−/− mice were generated by cross-
ing MCP-1flox/flox mice (JAX Stock No. 023347, B6;129-Ccl2 
<tm1Tyos>/J) (17, 18) to LysMCre mice (19). MyD88−/−, 
TLR2−/−, TLR4−/−, TLR9−/−, and IL-1R1−/− mice on a C57BL/6 
background were from the Cancer and Inflammation Program 
Mouse Core, NCI, Frederick. Mouse resident peritoneal cells 
(PC) were obtained by flushing the peritoneal cavity of C57BL/6 
mouse with 5  ml clod PBS. Mouse peritoneal exudate cells 
(PEC) were induced by intraperitoneal injection of 3% TG and 
harvested 3–4  days later. The experimental protocols of this 
study were approved by the Frederick National Laboratory for 
Cancer Research Animal Care and Use Committee, Frederick, 
MD, USA.
generation of 4T1 cell culture 
supernatant
Murine breast cancer 4T1 cells (ATCC, Manassas, VA, USA) were 
grown in RPMI-1640 containing 10% FBS, 1 mM glutamine, and 
antibiotics. Cell-free supernatants were collected by centrifugation 
at 1,200 rpm for 10 min. 4T1 cells were also grown in Ultradoma 
protein-free medium supplemented with 1% FBS, and cell-free 
culture supernatant was collected as described previously. Cell-
free supernatants were concentrated by using Amicon Centriprep 
10 or 30 (Amicon, Billerica, MA, USA).
column chromatography
Thirty milliliter of 4T1-sup containing 1% FBS was concentrated 
by CentriPrep (molecular weight cut off 3,000, EMD Millipore, 
Billerica, MA, USA) to 0.5 ml, filtered, and injected into a TSK-
2500 column (Tosoh Bioscience, King of Prussia, PA, USA). 
Four hundred microliter fractions were collected and assayed for 
MCP-1-inducing activity at 1:10 dilution.
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northern Blotting
Northern blot analysis was performed as described in 1.2% 
agarose gels containing formaldehyde (20). Filters were prehy-
bridized in Ultrahybri solution (Invitrogen) at 42°C for 1 h and 
then hybridized overnight in the presence of l × 106 dpm/ml of 
32P-labeled cDNA probe. Filters were washed twice with 2× SSC, 
0.1% SDS at 42°C for 10 min and 0.1× SSC, 0.1% SDS at 60°C 
for 30  min prior to autoradiographic exposure. The cloning of 
mouse MCP-1, MCP-3, and MCP-5 cDNA and human MCP-1 
and interleukin-8 (IL-8) was previously reported (17, 21, 22).
Quantification of cytokine/chemokine 
concentration
Mouse blood was drawn by heart puncture, and sera were iso-
lated and stored at −70°C until use. The concentration of MCP-1 
was measured in the Lymphokine Testing Laboratory, Clinical 
Services Program, SAIC-Frederick, Frederick, MD, USA or in 
our laboratory with an ELISA kit specific for mouse MCP-1 (R&D 
Systems). Cytokine levels in mouse serum and cell supernatant 
samples were analyzed using a Cytometric Bead Array Flex Set 
according to the manufacturer’s instructions on an LSR-II flow 
cytometer (BD Biosciences, Mountain View, CA, USA).
To quantitate MCP-1 levels in tumor tissues, tumors were 
homogenized in RIPA lysis buffer containing protease inhibitors. 
The homogenates were spun, and the supernatants were frozen 
at −20°C until use. The concentration of MCP-1 was analyzed 
by ELISA (R&D Systems). The concentration of total protein 
contained in the tumor lysates was determined by BCA protein 
assay kit (Pierce). The results are presented as picogram MCP-1/
milligram total protein in the sample.
activation of Macrophages In Vitro
Peritoneal exudate cells (PEC) were harvested by peritoneal 
lavage, using 5  ml cold PBS. After centrifugation, PEC were 
resuspended in RPMI-1640 containing 10% FBS, penicillin, and 
streptomycin, at the concentration of 2.5 × 106, and then cultured 
for indicated times in the presence or absence of stimuli.
To prepare human macrophages, 2 × 106 human monocytes 
were cultured in a six-well plate in 4 ml RPMI1640 containing 
10% FBS and 50 ng/ml recombinant human M-CSF for 7 days. 
Cells were incubated overnight in RPMI1640 without serum and 
then activated with 100 ng/ml LPS or different concentrations of 
recombinant human GM-CSF for 5  h. Total RNA was isolated 
and subjected to Northern blotting or quantative PCR (qPCR).
gene expression Profiling
Total RNA was extracted by TRIzol (Invitrogen), and the profile 
of gene expression was analyzed using the nCounter Analysis 
System (NanoString Technologies, Seattle, WA, USA) (23). The 
nCounter Code Set for the study contained 41 test and 2 control 
genes. The assay used two sequence-specific probes for each 
gene of interest. The probes were complementary to a 100-base 
region of the target mRNA. One probe was covalently linked to an 
oligonucleotide containing biotin (the capture probe); the other 
was linked to a color-coded molecular tag (reporter probe). Each 
hybridization consisted of 100 ng of total RNA, reporter, and cap-
ture probe mix for the 43 genes. The hybridization, washing, and 
scanning procedures were conducted according to the guidelines 
provided by NanoString Technologies.
qrT-Pcr
The expression of 47 cytokine and 28 chemokine genes was assessed 
by qRT-PCR. Total RNA was extracted from non-activated or 
activated PEC by using RNeasy mini kit (Qiagen). The quality 
and yield were assessed by Nanodrop spectrophotometry, and 
then cDNA was synthesized using High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). Real-time PCR was run 
on a Step One Plus Real-time PCR system (Applied Biosystems) 
using Power SYBR Green PCR Master Mix (Applied Biosystems) 
and Mouse Cytokine Primer Library I and II (RealTimePrimers.
com). The cycling condition was as follows: 10 min incubation 
at 95°C, followed by 50 cycles of 95°C for 15  s, and 60°C for 
1 min. The specificity of the PCR products was examined by a 
final melting curve analysis (95°C for 15 s, 60°C for 1 min, and 
95°C for 15 s). The fold expression or repression of the target gene 
relative to the internal control gene, β-actin, in each sample was 
calculated.
Treatment of Mice with anti-gM-csF 
antibody
4T1 cells were grown to 50–80% confluence. Before injection, 
cells were detached with 0.2% trypsin–EDTA, washed once 
with medium, three times with PBS, and resuspended in PBS 
at 1 ×  106 cells/ml. One hundred microliter of cell suspension 
(1 × 105 cells) were injected into the second mammary pad of six 
female Balb/c mice. Mice were separated into two groups; three 
mice in the control group received intraperitoneal injection of 
normal rat IgG (100 μg in 100 μl PBS) whereas three mice in 
the experiment group received anti-mouse GM-CSF IgG (100 μg 
in 100 μl PBS) twice a week, for 3  weeks. Blood was collected 
by mandibular puncture on day 14 and by heart puncture on 
day 28, and sera were isolated and stored at −80°C until use. 
Tumors and spleens were excised on day 28, and the infiltration 
of myeloid-derived suppressor cells (MDSCs) and macrophages 
was evaluated by flow cytometry. Lungs were perfused with 
Bouin’s solution, fixed in the same solution, and then the number 
of tumor nodules was counted by eye. In a separate experiment, 
1 × 105 4T1 cells (100 μl) were mixed with 10 μg of normal rat IgG 
or anti-GM-CSF IgG and injected into the second mammary pad 
of WT mice. Mice then received intra-tumor injection of 20 μg 
of normal rat IgG or anti-GM-CSF IgG on day 5 and 9, followed 
by 40 μg of normal rat IgG or anti-GM-CSF IgG on day 12. Blood 
was collected by mandibular puncture on day 14, and sera were 
isolated and stored at −80°C until use. Tumor size was measured, 
and tumor volume was calculated using the following formula: 
volume = (width)2 × length/2.
isolation of Tumor-infiltrating leukocytes
Tumors were dissected on day 28, homogenized using a 
GentleMACS dissociator (Miltenyi Biotech) and digested in RPMI 
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containing 5% FBS, 250 U/ml type IV collagenase (Invitrogen), 
100 μg/ml DNase I (Roche Molecular Biochemicals), and 1 mM 
EDTA (pH 8.0), at 37°C for 20 min. The homogenate was then 
processed in a tissue stomacher-80 (Seward) for 30  s, washed 
with HBSS, and resuspended in 40% Percoll (Amersham 
Pharmacia) in DMEM. The suspension was underlaid with 80% 
Percoll and centrifuged for 25  min at 1,000  ×  g. Leukocytes 
were collected from the interphase, washed, counted, and 
stained with anti-mouse antibodies, including FITC-CD45, 
APC-CD11b, PerCPCy5.5-Gr1, PerCPCy5.5-CD19, APC-CD8 
(BD Biosciences), PE-F4/80, APC eFluor 780-CD4, PE-CD25, 
and Pacific Blue-NKp46 (eBiosciences). Acquisition of data 
was performed using a LSRII, and data analysis was conducted 
using the FlowJo software (Tree Star Inc., Ashland, OR, USA). 
Only live cells determined using Sytox blue live/dead stain (Life 
Technologies) were analyzed.
statistical analysis
All experiments were performed at least twice. Results presented 
are from representative experiments. Statistical analysis was 
performed by Student’s t-test, using the GraphPad Prism, Version 
4 and 5, GraphPad Software, San Diego, CA, USA. A value of 
p < 0.05 was considered to be statistically significant.
resUlTs
4T1 cell Product(s) induces the 
expression of McP-1 and Other McPs in 
inflammatory Macrophages
To analyze the mechanisms by which infiltrating macrophages 
produce MCP-1 in 4T1 tumors, we first incubated mouse 
TG-induced PEC with tumor cells or with the culture supernatant 
of tumor cells (4T1-sup) for 24 h and measured the concentration 
of MCP-1 in the supernatants. As shown in Figure 1A, a low level 
of MCP-1 was detected in the culture supernatant of unstimulated 
TG-induced PEC (2.5 × 106 cells/ml). There was no detectable 
level of MCP-1 in the culture supernatant of 1 × 105 4T1 cells, 
but a low level of MCP-1 could be detected when the cell number 
was increased to 2 × 105. When PEC were co-cultured with 4T1 
cells or cultured in the presence of 50% (v/v) 4T1-sup, the level of 
MCP-1 in the culture supernatants was markedly increased in a 
manner dependent on the number of 4T1 cells (Figure 1A) or the 
concentration of 4T1-sup (Figure 1B). 4T1-sup did not increase 
the production of MCP-1 by TG-induced PEC from mice in 
which the MCP-1 gene was specifically deleted in myeloid cells, 
confirming that myeloid cells, especially macrophages, were the 
source of MCP-1 in the culture (Figure 1C).
To examine whether the effect of 4T1-sup was selective to MCP-
1, we examined the expression of several chemokines, including 
MCP-3/CCL7, MCP-5/CCL12, MIP-2/CXCL2, and KC/CXCL1 
by PEC, by Northern blotting. As shown in Figure 1D, 4T1-sup 
induced a high level of MCP-3 and a low level of MCP-5 mRNA, 
but the induction of neutrophil-attracting chemokines MIP-2 
or KC mRNA appeared to be minimal (lanes 2–5). In contrast, 
the TLR4 ligand LPS strongly induced the upregulation of all 
chemokines in PEC (lanes 6–9). TNFα induced only a low level 
of MCP-1 at 1 h (lanes 10–13). We also examined the production 
of tumor-promoting cytokines, such as TNFα or interleukin-6, 
by 4T1-sup-activated PEC (Figure 1E). There was a significant 
increase in the concentration of these cytokines in the culture 
supernatant, but the increase was much smaller than that by LPS. 
These results indicated that 4T1 cells have the capacity to activate 
macrophages to produce chemokines that recruit monocytes to 
shape the tumor microenvironment.
4T1 sup-induced McP-1 Production by 
Macrophages Was independent of TnFα, 
Tlr, or il-1r1 agonists
It is well known that tumor cells release proinflammatory media-
tors, such as TNFα (24), IL-1 (25), and TLR agonists (26), which 
activate macrophages. Therefore, we examined whether MCP-1 
production induced by 4T1 sup was due to these proinflam-
matory mediators by ELISA or Northern blotting. As shown in 
Figure 2A, addition of neutralizing antibody against TNFα had 
no effect on macrophage MCP-1 production induced by 4T1-sup. 
PEC deficient of MyD88, IL-1 R1, or TLR4 (HeJ mice) expressed 
MCP-1 mRNA whose level was comparable to that expressed by 
WT PEC (Figures 2B,C). These results indicated that 4T1-sup-
induced MCP-1 production by macrophages was not dependent 
on TNFα, IL-1, or TLR agonists that use MyD88 to transduce 
intracellular signals. Thus, 4T1 cells release other mediator(s) to 
activate macrophages for MCP-1 production.
gM-csF in 4T1-sup Was responsible for 
4T1-sup-induced McP-1 expression by 
Macrophages
To identify the 4T1 cell-derived molecule that activates mac-
rophages, we first attempted to determine its molecular mass. We 
prepared 4T1-sup in the absence or presence of 10% FBS and con-
centrated them on an Amicon membrane with a molecular mass 
cutoff of 10 (C10) or 30 kDa (C30). As shown in Figures 3A,B, the 
majority of MCP-1-inducing activity was retained on either filter, 
suggesting that the molecular mass of this molecule was larger 
than 30 kDa. Molecular sieve column chromatography showed a 
peak MCP-1-inducing activity in the fraction 26 and 27, which 
corresponded to the molecular mass of 20–26 kDa (Figure 3C).
4T1 cells were previously shown to express transcripts for 
myeloid cell growth factors, such as M-CSF/CSF-1, GM-CSF/
CSF-2, and G-CSF/CSF-3, and M-CSF was able to induce MCP-1 
production in macrophages (27), suggesting that M-CSF pro-
duced by 4T1 cells may be responsible for the increased MCP-1 
production by macrophages. Therefore, we examined the capacity 
of recombinant mouse M-CSF to induce MCP-1 expression by 
macrophages. As shown in Figure 4A, 4T1-sup dose-dependently 
induced high levels of MCP-1 mRNA expression in PEC (lanes 
2–7). M-CSF induced moderate levels of MCP-1 mRNA expres-
sion at its highest concentration of 100  ng/ml (lanes 8–10). In 
contrast, GM-CSF increased MCP-1 expression by PEC at as low 
as 1 ng/ml and its peak activity was detected at 10 ng/ml; thus 
GM-CSF is a potent inducer of MCP-1 in macrophages. Similar 
A B C
D E
FigUre 1 | a product of 4T1 cells induces McP-1 production by macrophages. (a) 1 × 105 or 2 × 105 4T1 cells were seeded into six-well plates. After 
overnight incubation at 37°C, medium was replaced by fresh medium, and 2.5 × 106 TG-induced PEC (Balb/c) or an equal volume of 4T1-sup were added. After 
24 h-incubation, cell-free culture supernatants were collected, and MCP-1 concentration in each supernatant was measured by MCP-1 ELISA. The results are 
shown as the mean ± SD, n = 3. (B) Five million TG-induced PEC were cultured in the presence of serially diluted 4T1-sup. After 24 h-incubation, cell-free media 
were collected, and MCP-1 concentration in each medium was measured by MCP-1 ELISA. The results are shown as the mean ± SD, n = 3. (c) Five million 
TG-induced PEC from MCP-1flox/flox or LysMCre+/MCP-1flox/flox mice were incubated in the presence of 100 ng/ml LPS or 4T1 supernatant. After 24 h-incubation, 
cell-free media were collected, and MCP-1 concentration in each medium was measured by MCP-1 ELISA. The results are shown as the mean ± SD, n = 3.  
(D) Two and half million TG-induced PEC were incubated in the presence or absence of 4T1-sup (1:1), 100 ng/ml LPS, or 10 ng/ml TNFα. Total RNA was extracted 
and subjected to Northern blotting. (e) Two million TG-induced PEC were cultured in the presence of 4T1-sup (1:1). After 24 h-incubation, cell-free media were 
collected, and TNFα or IL-6 concentration in each medium was measured by Cytometric Bead Array. The results are shown as the mean ± SD, n = 2.
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to 4T1-sup, recombinant GM-CSF induced a high level of MCP-1 
mRNA, but not KC mRNA, by Northern blotting (Figure 4A).
We next used neutralizing antibodies and found that anti-GM-
CSF Ab, but not anti-M-CSF Ab, almost completely abrogated 
4T1-sup-induced MCP-1 expression by PEC (Figure 4B). There 
was no additional inhibition when both antibodies were used 
together. The results of MCP-1 mRNA expression were validated by 
the results of MCP-1 protein production (Figures 4C,D). Human 
recombinant GM-CSF also dose-dependently induced high levels 
of MCP-1, but not IL-8, expression in human monocyte-derived 
macrophages (Figure 4E). Thus, GM-CSF is a potent inducer of 
MCP-1 in macrophages, and GM-CSF produced by breast cancer 
cells may contribute to the elevated MCP-1 production in tumor 
stroma. In fact, GM-CSF was highly expressed in 4T1 tumors 
(Figure 5A), but not in tumors generated by the subcutaneous 
injection of the mouse lung cancer LLC cells. In contrast, M-CSF 
was more highly expressed in LLC tumors than in 4T1 tumors 
(Figure 5B).
The results of Northern blotting shown above suggested 
that GM-CSF, unlike LPS that potently induces a wide variety 
of cytokine and chemokine genes by macrophages, might 
induce a selective set of cytokine and chemokine genes. 
Therefore, we examined the expression of 47 cytokine and 28 
chemokine genes by GM-CSF-activated mouse macrophages 
by qRT-PCR and compared with that by LPS-activated mac-
rophages. GM-CSF highly induced the expression of several 
AB
C
FigUre 2 | Macrophage production of McP-1 in response to 
stimulation by 4T1 supernatant is independent of TnFα, il-1r1, Tlr4, 
or MyD88. (a) Five million WT TG-induced PEC were incubated in the 
presence or absence of 4T1-sup (1:1) or 10 ng/ml TNFα for 24 h and the 
concentration of MCP-1 in cell-free culture supernatants was measured by 
ELISA. To neutralize TNFα, 10 μg neutralizing anti-TNFα IgG was added to 
the culture. The results are shown as the mean ± SD, n = 2. (B) Two and half 
million TG-induced PEC from WT or MyD88−/− mice were cultured for 4 h in 
the presence of 100 ng/ml LPS or 4T1-sup. Total RNA was isolated and 
subjected to Northern blotting. (c) Two and half million TG-induced PEC from 
WT or MyD88−/−, IL-1R1−/−, C3H/HeN (TLR4+/+), or C3H/HeJ (TLR4−/−) mice 
were cultured for 4 h in the presence of 4T1-sup (1:1). Total RNA was 
isolated and subjected to Northern blotting.
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from those induced by LPS in mouse macrophages (Table S1 
in Supplementary Material).
neutralization of gM-csF Did not reduce 
either McP-1 Production or lung 
Metastasis in Tumor-Bearing Mice
The results of our in vitro study suggested that GM-CSF secreted 
by tumor cells regulate the production of MCP-1 in 4T1 tumors; 
therefore, neutralization of GM-CSF in tumor-bearing mice may 
reduce MCP-1 production in 4T1 tumor microenvironment 
and subsequent lung metastasis of 4T1 cells. We first examined 
whether neutralization of GM-CSF directly affects the growth 
of 4T1 cells in  vitro. Ten thousands 4T1 cells were seeded in 
six-well culture plates and incubated at 37°C for 4 or 5 days in 
the presence of normal rat IgG or anti-GM-CSF Ab. Addition of 
anti-GM-CSF Ab had no direct effect on the growth of 4T1 cells 
(data not shown).
We next treated the mice with intraperitoneal injection of 
either normal rat IgG or anti-GM-CSF Ab (100 μg per mouse) 
six times (Figure 6A) to examine the role of tumor-cell-derived 
GM-CSF in MCP-1 production and tumor progression. As 
shown in Figure 6B, injection of anti-GM-CSF Ab significantly 
delayed the growth of primary tumors at an early stage, especially 
from day 11 to 15, but this effect became less significant at a later 
stage (after day 19). Either serum MCP-1 concentration or tumor 
MCP-1 content was not significantly different between the two 
mouse groups (Figures 6C,D), and mice treated with anti-GM-
CSF Ab developed lung metastasis similar to those treated with 
normal rat IgG (Figure 6E). Enlargement of spleens was observed 
in both group with similar numbers of splenocytes (Figure 6F). 
Furthermore, the percentage of MDSCs and macrophages infil-
trating the primary tumors was similar between the two groups 
(Figure 6G). The distribution of macrophages in tumors was also 
similar between the two groups (data not shown). Intratumoral 
injection of anti-GM-CSF Ab also significantly reduced tumor 
volume on day 7, 15, and 19, but did not reduce the serum 
MCP-1 concentration 2 weeks after the injection of tumor cells 
(Figures  7A,B). These results indicate that tumor cell-derived 
GM-CSF appears to play a role in promoting tumor development, 
but it is unlikely a major factor involved in MCP-1 production in 
4T1 tumor microenvironment in vivo.
DiscUssiOn
Tumor microenvironment consists of a variety of cell types, 
including tumor cells, fibroblasts, endothelial cells, myocytes, 
and inflammatory cells, such as MDSCs, regulatory T cells, mac-
rophages, and dendritic cells. The interaction of tumor cells with 
stromal cells leads to the production of an array of mediators that 
provide the soil for tumor cells to grow, invade, and metastasize 
(28–30). We previously reported that the chemokine MCP-1 pro-
duced by non-tumor cells in tumor stroma, both hematopoietic 
and non-hematopoietic cells, promoted spontaneous lung metas-
tasis of 4T1 breast cancer cells (16). However, the mechanisms 
by which stromal cells in 4T1 tumor microenvironment produce 
MCP-1 remain unclear. In the present study, we examined 
cytokine genes, including TNFα, TNF subfamily member 
11 (Trance/RankL), IL-1 family member 8 (IL-36B), and 
chemokine genes, including CXCL1, CXCL2, CXCL5, CCL2, 
CCL3, CCL7, CCL17, and CCL28. However, the expression 
of TNFα, CXCL1 (KC), and CXCL2 (MIP-2) was much lower 
than that induced by LPS. The expression of other genes 
highly induced by LPS, such as IL-1α, IL-1β, IL-1 member 6, 
IL-6, IL-17F, CXCL12, and CCL5, was also low in GM-CSF-
activated macrophages. Thus, GM-CSF induces the expression 
of a set of cytokine and chemokine genes that are different 
AB
C
FigUre 3 | Partial characterization of McP-1-inducing activity in 4T1-sup. Cell-free 4T1-sup containing 10% FBS (a) or without FBS (B) was concentrated 
by using Amicon Centriprep 10 or 30, and then total volume was adjusted to the original volume by adding RPMI-1640. MCP-1-inducing activity was examined by 
Northern blotting. (c) Thirty milliliter of 4T1-sup containing 1% FBS was concentrated by CentriPrep, filtered, and injected into a TSK-2500 column. Four hundred 
micro liter fractions were collected and assayed for MCP-1-inducing activity at 1:10 dilution. The fractions to which molecular mass markers were eluted are 
indicated by arrows.
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whether 4T1 cells directly activate inflammatory macrophages, 
an important cellular component of tumor stroma, and found that 
GM-CSF produced and released by 4T1 cells potently induces 
MCP-1 production by mouse inflammatory macrophages.
In breast cancer, macrophages constitute up to 35% of the infil-
trating inflammatory cells (31), and the behavior of macrophages 
is conditioned by cytokines produced in a tumor microenviron-
ment. The macrophage growth factor M-CSF is expressed in over 
70% of human breast cancers (32). Serum M-CSF levels correlate 
with tumor size, metastasis, and poor outcomes in humans (33, 
34). Mice deficient in M-CSF are protected against breast tumor 
metastasis, and re-expressing M-CSF solely in the breast tissue 
restores tumor metastatic capacity (35). M-CSF was shown to 
induce leukocytes to produce cytokines, including IL-1β and 
TNFα, and chemokines, including MCP-1 (36). These findings 
led us to hypothesize that M-CSF might be responsible for 
4T1-sup-induced MCP-1 production by macrophages. Although 
the expression of M-CSF was detected in 4T1 tumor micro-
environment, M-CSF was a weak inducer of MCP-1 in mouse 
inflammatory macrophages in vitro. Furthermore, neutralization 
of M-CSF did not affect the activity of 4T1-sup to induce MCP-1 
production. These results indicate that M-CSF does not play a 
A B
C
D E
FigUre 4 | gM-csF produced by 4T1 cells is responsible for the McP-1 expression by macrophages. (a) Two and half million TG-induced PEC from WT 
mice were cultured for 4 h in the presence of different concentration of 4T1-sup, mouse recombinant M-CSF or GM-CSF for 4 h. Total RNA was isolated and 
subjected to Northern blotting. (B) Two and half million TG-induced PEC from WT mice were cultured for 4 h with 4T1-sup in the presence or absence of 
neutralizing antibody against mouse M-CSF or GM-CSF for 4 h. Total RNA was isolated and subjected to Northern blotting. (c) Two million TG-induced PEC from 
WT mice were cultured for 24 h in the presence of different concentrations of recombinant mouse GM-CSF, M-CSF, or LPS. Cell-free culture supernatants were 
obtained, and the concentration of MCP-1 or KC was measured by ELISA for MCP-1 and by Cytometric Bead Array for KC. The results are shown as the 
mean ± SD, n = 2. (D) Two million TG-induced PEC from WT mice were cultured for 24 h with 4T1-sup in the presence or absence of neutralizing antibody against 
mouse M-CSF or GM-CSF. Cell-free culture supernatants were obtained and the concentration of MCP-1 was measured by ELISA. The results are shown as the 
mean ± SD, n = 2. (e) Human monocyte-derived macrophages were cultured with 100 ng/ml LPS or different concentrations of recombinant human GM-CSG for 
4 h. Total RNA was isolated and subjected to Northern blotting.
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major role in macrophage expression of MCP-1 in 4T1 breast 
cancer.
Granulocyte/macrophage colony-stimulating factor, another 
macrophage growth factor, is produced by a wide variety of cells, 
including cancer cells (37). Recently, mesenchymal-like human 
breast cancer cells were demonstrated to produce GM-CSF 
and cancer cell-derived GM-CSF transformed macrophages to 
a TAM-like phenotype and to produce the chemokine CCL18, 
leading to the promotion of metastasis to the lung and liver in 
humanized mice (38). GM-CSF was highly expressed in about 
AB
FigUre 5 | expression of M-csF or gM-csF in 4T1 or llc tumors. 
The expression of GM-CSF (a) or M-CSF (B) mRNA in 4T1 tumors or LLC 
tumors was examined by Nanostring gene profiling. The results are shown as 
the mean ± SEM, n = 5 for 4T1 tumors and n = 4 for LLC tumors.
January 2016 | Volume 7 | Article 29
Yoshimura et al. Macrophages Production of MCP-1 by Tumor-Cell-Derived GM-CSF
Frontiers in Immunology | www.frontiersin.org
29% of human breast cancer samples, and the infiltration of 
CCL18-positive macrophages was often observed at the invasive 
front of tumors, where cancer cells displayed more mesenchymal 
features and expressed high levels of GM-CSF. These finding led 
the authors to the conclusion that GM-CSF-CCL18 loop plays a 
critical role in the progression of breast cancer (38). In another 
study, in vitro co-culture of human MDA-MB-231 breast cancer 
cells with mouse macrophages led to the upregulation of MCP-1 
production by mouse macrophages (39); however, the mecha-
nisms by which breast cancer cells upregulate MCP-1 production 
by macrophages remain uncharacterized.
In the present study, we first detected that a product(s) of 4T1 
mouse breast cancer cells could upregulate MCP-1 production 
by macrophages. The majority of the MCP-1-inducing activity 
was retained after filtration through a membrane with a molecu-
lar weight cut off of 30 kDa, suggesting that the molecular mass 
of the 4T1 product might be larger than 30 kDa. However, the 
results of HPLC gel-filtration indicated that the molecular mass 
of the 4T1 product was approximately 20–26 kDa, significantly 
smaller than that obtained by the membrane. This 4T1 cell 
product was subsequently identified as GM-CSF using a neutral-
izing antibody against GM-CSF. The apparent molecular mass 
of GM-CSF purified from mouse lung-conditioned medium 
was approximately 29 kDa by gel-filtration and 23 kDa by elec-
trophoresis (40). Thus, the molecular mass of the 4T1 product 
we identified as GM-CSF was similar to that of purified natural 
mouse GM-CSF. The membrane we used was characterized by a 
nominal molecular weight limit, but its retaining capacity may 
be affected by other factors, such as physicochemical charac-
teristics and behavior in a particular solution of each protein. 
In fact, as reported by the manufacturer of the membrane, 70% 
of α-chymotrypsinogen whose molecular mass was 25 kDa was 
retained by the same membrane. This may explain the reason 
why the majority of the MCP-1-inducing activity was retained 
by this membrane despite that the molecular mass of GM-CSF 
is smaller than 30 kDa.
Granulocyte/macrophage colony-stimulating factor induces 
a high level of MCP-1 expression and/or production in both 
mouse and human macrophages at a concentration as low as 
1  ng/ml. Interestingly, it induces only a modest level of KC or 
MIP-2 expression, and the expression level of these neutrophil 
chemotactic chemokines was much lower than that induced 
by the TLR4 ligand LPS. Furthermore, GM-CSF upregulates 
the expression of certain genes whose expression was not 
significantly upregulated by LPS, indicating that GM-CSF 
preferentially induce the expression of a unique set of genes, 
including MCP-1. Our results strongly suggest that in addition 
to the GM-CSF-CCL18 loop noted above, the GM-CSF-MCP-1 
(CCL2) loop is also present in breast cancer. Both CCL18 and 
MCP-1 can promote breast cancer progression in human. Since 
CCL18 is absent in mice (41), it is plausible that MCP-1 may act 
as a chemokine counterpart of human CCL18 for breast cancer 
progression in mice. In contrast to the tumor-promoting activity 
of endogenously produced GM-CSF, exogenously administered 
GM-CSF elicits potent immune responses and thus is used in 
tumor therapies as an immune adjuvant (42). Therefore, it will 
be important to delineate how the administration of exogenous 
GM-CSF affects the GM-CSF-CCL18 or GM-CSF-MCP-1 loop 
created by endogenous GM-CSF. The availability of GM-CSF in 
different locations of cancer subjects may be critical to enhance 
the immune system.
Although tumor-cell-derived GM-CSF markedly upregulated 
MCP-1 production by macrophages in  vitro, neutralization of 
GM-CSF in tumor-bearing mice showed little effect on serum 
MCP-1 concentration or tumor MCP-1 content, strongly suggest-
ing that the GM-CSF is not a major regulator of MCP-1 produc-
tion in 4T1 tumor microenvironment. Furthermore, there was no 
reduction in the number of metastatic lung tumors, the number 
of splenocytes, or the percentage of tumor-infiltrating MDSCs or 
macrophages in tumor-bearing mice treated with anti-GM-CSF 
Ab. These results indicate the presence of GM-CSF-independent 
mechanisms, which upregulate MCP-1 production in breast 
cancer tumor microenvironments. Macrophage production of 
MCP-1 can be upregulated by other molecules, including TLR 
ligands. This may explain why neutralization of GM-CSF did 
not result in the reduction of MCP-1 production as evidenced 
by similar serum MCP-1 levels in control and anti-GM-CSF 
Ab-treated mice. It is also well known that other cellular com-
ponents of tumor stroma, such as fibroblasts or endothelial cells, 
produce MCP-1 in response to stimulation (43). Co-culture of 
human fibroblasts with human breast cancer cells tumor previ-
ously resulted in the production of MCP-1 by fibroblasts (44), 
suggesting that fibroblasts can be an important cellular source 
of MCP-1 in tumor microenvironments. We will explore this 
possibility in the future.
Unlike MCP-1−/− mice in which lung metastasis, but not the 
size of tumors at the injected site, was reduced (16), anti-GM-CSF 
AB
D E
F
G
C
FigUre 6 | anti-gM-csF treatment of 4T1 tumor-bearing mice had a limited effect on tumor progression. (a) The scheme of systemic antibody treatment 
is shown. One hundred micro gram of either control rat IgG or anti-GM-CSF Ab was intraperitoneally injected on day 0, 3, 7, 10, 14, 18. Mice were euthanized on 
day 28. (B) The size of tumor in each mouse was measured, and the volume was calculated. The results are shown as the mean ± SD, n = 3, *p < 0.05, **p < 0.01. 
(c) Serum samples were collected on day 14 and day 28, and the MCP-1 concentration was measured by ELISA. The results are shown as the mean ± SD, n = 3. 
(D) Tumors were homogenized in RIPA lysis buffer-containing protease inhibitors and the homogenates were spun and the supernatants were frozen at −20°C until 
use. The concentration of MCP-1 was analyzed by ELISA, and the concentration of total protein in the tumor lysates was determined by BCA protein assay kit. The 
results are shown as the mean ± SD, n = 5. (e) The number of tumor nodules on the lung of each mouse was counted on day 28. The results are shown as the 
mean ± SD, n = 3. (F) The number of splenocytes of each mouse was counted on day 28. The results are shown as the mean ± SD, n = 3. (g) The percentage of 
tumor-infiltrating CD11b+Gr1lowF4/80− MDSC or F4/80+ macrophages in CD45+ cells was analyzed by flow cytometry. The number of tumor nodules on the lung of 
each mouse was counted on day 28. The results are shown as the mean ± SD, n = 3.
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A B
FigUre 7 | intratumoral injection of anti-gM-csF had a limited effect on tumor progression in 4T1 tumor-bearing mice. (a) 1 × 105 4T1 cells (100 μl) 
were mixed with 10 μg of normal rat IgG or anti-GM–CSF IgG and injected into the second mammary pad of WT mice. Mice were then received intra-tumor injection 
of 20 μg of normal rat IgG or anti-GM-CSF IgG on day 5 and 9, followed by 40 μg of normal rat IgG or anti-GM-CSF IgG on day 12, 16, and 19. The size of tumor in 
each mouse was measured and the volume was calculated. The results are shown as the mean ± SD, n = 5, *p < 0.05, **p < 0.01. (B) Blood was collected by 
mandibular puncture on day 14, sera were isolated, and MCP-1 concentration was measured by ELISA. The results are shown as the mean ± SEM, n = 5.
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treatment significantly reduced tumor size without affecting 
the level of lung metastasis. In the present study, we found that 
GM-CSF activates macrophages and induces the expression of 
MCP-1. However, MCP-1 may not be the only cytokine whose 
expression is upregulated by GM-CSF in tumor microenviron-
ments. Macrophages cultured with GM-CSF were previously 
demonstrated to become cells capable of producing TNFα or 
IL-6 following stimulation with the TLR4 ligand LPS (45, 46). 
In fact, we detected these cytokines in the culture supernatant 
of 4T1-sup-activated macrophages by ELISA and upregulation of 
mRNA expression by GM-CSF-activated macrophages by qRT-
PCR. In addition, GM-CSF induced the upregulation of several 
other genes whose products could also potentially promote tumor 
growth. GM-CSF was also shown to stimulate granulocytes to 
produce prostaglandin E and leukotriene B4, which can dampen 
antitumor immune responses (45–47). Thus, GM-CSF produced 
by tumors cells can promote tumor growth by inducing the pro-
duction of multiple tumor-promoting cytokines and chemokines 
by macrophages and by activating neutrophils. This may explain 
the reason why the neutralization of GM-CSF resulted in reduced 
4T1 tumor growth. Further studies are necessary to identify the 
precise role of tumor cell-derived GM-CSF in tumor development.
A number of proinflammatory mediators are present in tumor 
microenvironments, which are produced by either tumor cells or 
stromal cells. Although in some tumor cells, the production of 
proinflammatory mediators is intrinsically upregulated, the inter-
action of tumor cells with stromal cells is a key factor for upregu-
lated production of certain tumor-promoting proinflammatory 
mediators. We recently revealed that Lewis lung carcinoma cells 
activate mouse macrophages to produce TNFα which in turn 
activates Lewis lung carcinoma cells to produce a large amount 
of MCP-1 (48). Additional studies identifying the mechanisms of 
tumor cell-stromal cell interaction and molecule(s) responsible 
for the induction of tumor-promoting mediators are necessary to 
provide a new means to target tumor microenvironment.
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